Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study
The optimal timing of treatment escalation in Crohn's disease [CD] remains a challenging issue, and very little is known about its long-term development following early versus late administration of anti-TNF antibodies. The long-term outcome of Swiss CD patients was comparatively assessed in an...
Gespeichert in:
| Veröffentlicht in: | Journal of Crohn's and colitis 2019-09, Vol.13 (10), p.1292-1301 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1301 |
|---|---|
| container_issue | 10 |
| container_start_page | 1292 |
| container_title | Journal of Crohn's and colitis |
| container_volume | 13 |
| creator | Frei, Roy Fournier, Nicolas Zeitz, Jonas Scharl, Michael Morell, Bernhard Greuter, Thomas Schreiner, Philipp Misselwitz, Benjamin Safroneeva, Ekaterina Schoepfer, Alain M Vavricka, Stephan R Rogler, Gerhard Biedermann, Luc |
| description | The optimal timing of treatment escalation in Crohn's disease [CD] remains a challenging issue, and very little is known about its long-term development following early versus late administration of anti-TNF antibodies. The long-term outcome of Swiss CD patients was comparatively assessed in an up to 10-year follow-up, using patients participating in the Swiss Inflammatory Bowel Disease Cohort Study [SIBDCS].
Prospectively collected SIBDCS patient data, including disease history, baseline characteristics at enrolment, and course of disease, were analysed in patients with early versus late [ |
| doi_str_mv | 10.1093/ecco-jcc/jjz057 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2190109593</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2190109593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c338t-9d44de3c7dd0e24270b43bc7b9c8c584a1285ed1c360b64f1858df72cbdcea73</originalsourceid><addsrcrecordid>eNo9kcGO0zAQhi0EYpeFMzc0N7iYOrFdO9y67RYqVexhe-EUOfaEukriYjtU5UV4XbJ04TQjzTf_4f8IeVuwjwWr-AytDfRg7exw-MWkekauC63mVAhVPf-7c1pVYn5FXqV0YExWUumX5IozLYUU-pr8vjOxO8Nm8Nmb7MMAoYXFkD3dfV2DT7BIKdjphA5OPu9hbX6GMZqmQ9iG4TvNGHu4H7MNPYIfYBnDfnifYOUTmoSfoGD0G5pI16HrwomOR1iZbKCNoYe8R3g4-ZRgc7uCZdiHmOEhj-78mrxoTZfwzdO8Ibv13W75hW7vP2-Wiy21nOtMKyeEQ26VcwxLUSrWCN5Y1VRWW6mFKUot0RWWz1kzF22hpXatKm3jLBrFb8iHS-wxhh8jplz3PlnsOjNgGFNdFhWbipYVn9DZBbUxpBSxrY_R9yae64LVjzLqRxn1JKO-yJg-3j2Fj02P7j__r33-B24xiOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2190109593</pqid></control><display><type>article</type><title>Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Frei, Roy ; Fournier, Nicolas ; Zeitz, Jonas ; Scharl, Michael ; Morell, Bernhard ; Greuter, Thomas ; Schreiner, Philipp ; Misselwitz, Benjamin ; Safroneeva, Ekaterina ; Schoepfer, Alain M ; Vavricka, Stephan R ; Rogler, Gerhard ; Biedermann, Luc</creator><creatorcontrib>Frei, Roy ; Fournier, Nicolas ; Zeitz, Jonas ; Scharl, Michael ; Morell, Bernhard ; Greuter, Thomas ; Schreiner, Philipp ; Misselwitz, Benjamin ; Safroneeva, Ekaterina ; Schoepfer, Alain M ; Vavricka, Stephan R ; Rogler, Gerhard ; Biedermann, Luc</creatorcontrib><description>The optimal timing of treatment escalation in Crohn's disease [CD] remains a challenging issue, and very little is known about its long-term development following early versus late administration of anti-TNF antibodies. The long-term outcome of Swiss CD patients was comparatively assessed in an up to 10-year follow-up, using patients participating in the Swiss Inflammatory Bowel Disease Cohort Study [SIBDCS].
Prospectively collected SIBDCS patient data, including disease history, baseline characteristics at enrolment, and course of disease, were analysed in patients with early versus late [<24 versus ≥24 months after diagnosis] and no anti-TNF treatment.
A reduced risk of developing bowel stenosis was found in patients who received early anti-TNF treatment. This association was seen in patients overall and also in the subgroups of CD patients without pre-existing complications [Log-rank test: p < 0.001].Furthermore, osteoporosis and anaemia were observed significantly less frequently in patients who received early anti-TNF treatment, compared with either patients who received treatment late [p < 0.001 and p = 0.046, respectively] or were never [p < 0.001 for both] treated with anti-TNF antibodies. Patients with early anti-TNF administration sought medical consultations significantly less often, including gastroenterologists in private practice [p = 0.017], ambulatory [outpatient] hospital visits [p = 0.038], and a composite of any medical visits [p = 0.001]. The percentage of patients unable to work was lowest for early-anti-TNF-treated patients, in comparison with patients who were treated late or never [3.6% vs 8.8% vs 3.7%, p = 0.016].
In CD patients within the SIBDCS, early anti-TNF administration was found to be associated with several indicators of a more favourable long-term outcome.</description><identifier>ISSN: 1873-9946</identifier><identifier>EISSN: 1876-4479</identifier><identifier>DOI: 10.1093/ecco-jcc/jjz057</identifier><identifier>PMID: 30854548</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - adverse effects ; Anti-Inflammatory Agents - therapeutic use ; Crohn Disease - complications ; Crohn Disease - drug therapy ; Female ; Follow-Up Studies ; Humans ; Intestinal Obstruction - epidemiology ; Intestinal Obstruction - etiology ; Intestinal Obstruction - prevention & control ; Male ; Middle Aged ; Prospective Studies ; Switzerland ; Time Factors ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Journal of Crohn's and colitis, 2019-09, Vol.13 (10), p.1292-1301</ispartof><rights>Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c338t-9d44de3c7dd0e24270b43bc7b9c8c584a1285ed1c360b64f1858df72cbdcea73</citedby><cites>FETCH-LOGICAL-c338t-9d44de3c7dd0e24270b43bc7b9c8c584a1285ed1c360b64f1858df72cbdcea73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30854548$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frei, Roy</creatorcontrib><creatorcontrib>Fournier, Nicolas</creatorcontrib><creatorcontrib>Zeitz, Jonas</creatorcontrib><creatorcontrib>Scharl, Michael</creatorcontrib><creatorcontrib>Morell, Bernhard</creatorcontrib><creatorcontrib>Greuter, Thomas</creatorcontrib><creatorcontrib>Schreiner, Philipp</creatorcontrib><creatorcontrib>Misselwitz, Benjamin</creatorcontrib><creatorcontrib>Safroneeva, Ekaterina</creatorcontrib><creatorcontrib>Schoepfer, Alain M</creatorcontrib><creatorcontrib>Vavricka, Stephan R</creatorcontrib><creatorcontrib>Rogler, Gerhard</creatorcontrib><creatorcontrib>Biedermann, Luc</creatorcontrib><title>Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study</title><title>Journal of Crohn's and colitis</title><addtitle>J Crohns Colitis</addtitle><description>The optimal timing of treatment escalation in Crohn's disease [CD] remains a challenging issue, and very little is known about its long-term development following early versus late administration of anti-TNF antibodies. The long-term outcome of Swiss CD patients was comparatively assessed in an up to 10-year follow-up, using patients participating in the Swiss Inflammatory Bowel Disease Cohort Study [SIBDCS].
Prospectively collected SIBDCS patient data, including disease history, baseline characteristics at enrolment, and course of disease, were analysed in patients with early versus late [<24 versus ≥24 months after diagnosis] and no anti-TNF treatment.
A reduced risk of developing bowel stenosis was found in patients who received early anti-TNF treatment. This association was seen in patients overall and also in the subgroups of CD patients without pre-existing complications [Log-rank test: p < 0.001].Furthermore, osteoporosis and anaemia were observed significantly less frequently in patients who received early anti-TNF treatment, compared with either patients who received treatment late [p < 0.001 and p = 0.046, respectively] or were never [p < 0.001 for both] treated with anti-TNF antibodies. Patients with early anti-TNF administration sought medical consultations significantly less often, including gastroenterologists in private practice [p = 0.017], ambulatory [outpatient] hospital visits [p = 0.038], and a composite of any medical visits [p = 0.001]. The percentage of patients unable to work was lowest for early-anti-TNF-treated patients, in comparison with patients who were treated late or never [3.6% vs 8.8% vs 3.7%, p = 0.016].
In CD patients within the SIBDCS, early anti-TNF administration was found to be associated with several indicators of a more favourable long-term outcome.</description><subject>Adult</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - adverse effects</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Crohn Disease - complications</subject><subject>Crohn Disease - drug therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Intestinal Obstruction - epidemiology</subject><subject>Intestinal Obstruction - etiology</subject><subject>Intestinal Obstruction - prevention & control</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Switzerland</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>1873-9946</issn><issn>1876-4479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kcGO0zAQhi0EYpeFMzc0N7iYOrFdO9y67RYqVexhe-EUOfaEukriYjtU5UV4XbJ04TQjzTf_4f8IeVuwjwWr-AytDfRg7exw-MWkekauC63mVAhVPf-7c1pVYn5FXqV0YExWUumX5IozLYUU-pr8vjOxO8Nm8Nmb7MMAoYXFkD3dfV2DT7BIKdjphA5OPu9hbX6GMZqmQ9iG4TvNGHu4H7MNPYIfYBnDfnifYOUTmoSfoGD0G5pI16HrwomOR1iZbKCNoYe8R3g4-ZRgc7uCZdiHmOEhj-78mrxoTZfwzdO8Ibv13W75hW7vP2-Wiy21nOtMKyeEQ26VcwxLUSrWCN5Y1VRWW6mFKUot0RWWz1kzF22hpXatKm3jLBrFb8iHS-wxhh8jplz3PlnsOjNgGFNdFhWbipYVn9DZBbUxpBSxrY_R9yae64LVjzLqRxn1JKO-yJg-3j2Fj02P7j__r33-B24xiOA</recordid><startdate>20190927</startdate><enddate>20190927</enddate><creator>Frei, Roy</creator><creator>Fournier, Nicolas</creator><creator>Zeitz, Jonas</creator><creator>Scharl, Michael</creator><creator>Morell, Bernhard</creator><creator>Greuter, Thomas</creator><creator>Schreiner, Philipp</creator><creator>Misselwitz, Benjamin</creator><creator>Safroneeva, Ekaterina</creator><creator>Schoepfer, Alain M</creator><creator>Vavricka, Stephan R</creator><creator>Rogler, Gerhard</creator><creator>Biedermann, Luc</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190927</creationdate><title>Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study</title><author>Frei, Roy ; Fournier, Nicolas ; Zeitz, Jonas ; Scharl, Michael ; Morell, Bernhard ; Greuter, Thomas ; Schreiner, Philipp ; Misselwitz, Benjamin ; Safroneeva, Ekaterina ; Schoepfer, Alain M ; Vavricka, Stephan R ; Rogler, Gerhard ; Biedermann, Luc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c338t-9d44de3c7dd0e24270b43bc7b9c8c584a1285ed1c360b64f1858df72cbdcea73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - adverse effects</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Crohn Disease - complications</topic><topic>Crohn Disease - drug therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Intestinal Obstruction - epidemiology</topic><topic>Intestinal Obstruction - etiology</topic><topic>Intestinal Obstruction - prevention & control</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Switzerland</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frei, Roy</creatorcontrib><creatorcontrib>Fournier, Nicolas</creatorcontrib><creatorcontrib>Zeitz, Jonas</creatorcontrib><creatorcontrib>Scharl, Michael</creatorcontrib><creatorcontrib>Morell, Bernhard</creatorcontrib><creatorcontrib>Greuter, Thomas</creatorcontrib><creatorcontrib>Schreiner, Philipp</creatorcontrib><creatorcontrib>Misselwitz, Benjamin</creatorcontrib><creatorcontrib>Safroneeva, Ekaterina</creatorcontrib><creatorcontrib>Schoepfer, Alain M</creatorcontrib><creatorcontrib>Vavricka, Stephan R</creatorcontrib><creatorcontrib>Rogler, Gerhard</creatorcontrib><creatorcontrib>Biedermann, Luc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Crohn's and colitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frei, Roy</au><au>Fournier, Nicolas</au><au>Zeitz, Jonas</au><au>Scharl, Michael</au><au>Morell, Bernhard</au><au>Greuter, Thomas</au><au>Schreiner, Philipp</au><au>Misselwitz, Benjamin</au><au>Safroneeva, Ekaterina</au><au>Schoepfer, Alain M</au><au>Vavricka, Stephan R</au><au>Rogler, Gerhard</au><au>Biedermann, Luc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study</atitle><jtitle>Journal of Crohn's and colitis</jtitle><addtitle>J Crohns Colitis</addtitle><date>2019-09-27</date><risdate>2019</risdate><volume>13</volume><issue>10</issue><spage>1292</spage><epage>1301</epage><pages>1292-1301</pages><issn>1873-9946</issn><eissn>1876-4479</eissn><abstract>The optimal timing of treatment escalation in Crohn's disease [CD] remains a challenging issue, and very little is known about its long-term development following early versus late administration of anti-TNF antibodies. The long-term outcome of Swiss CD patients was comparatively assessed in an up to 10-year follow-up, using patients participating in the Swiss Inflammatory Bowel Disease Cohort Study [SIBDCS].
Prospectively collected SIBDCS patient data, including disease history, baseline characteristics at enrolment, and course of disease, were analysed in patients with early versus late [<24 versus ≥24 months after diagnosis] and no anti-TNF treatment.
A reduced risk of developing bowel stenosis was found in patients who received early anti-TNF treatment. This association was seen in patients overall and also in the subgroups of CD patients without pre-existing complications [Log-rank test: p < 0.001].Furthermore, osteoporosis and anaemia were observed significantly less frequently in patients who received early anti-TNF treatment, compared with either patients who received treatment late [p < 0.001 and p = 0.046, respectively] or were never [p < 0.001 for both] treated with anti-TNF antibodies. Patients with early anti-TNF administration sought medical consultations significantly less often, including gastroenterologists in private practice [p = 0.017], ambulatory [outpatient] hospital visits [p = 0.038], and a composite of any medical visits [p = 0.001]. The percentage of patients unable to work was lowest for early-anti-TNF-treated patients, in comparison with patients who were treated late or never [3.6% vs 8.8% vs 3.7%, p = 0.016].
In CD patients within the SIBDCS, early anti-TNF administration was found to be associated with several indicators of a more favourable long-term outcome.</abstract><cop>England</cop><pmid>30854548</pmid><doi>10.1093/ecco-jcc/jjz057</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1873-9946 |
| ispartof | Journal of Crohn's and colitis, 2019-09, Vol.13 (10), p.1292-1301 |
| issn | 1873-9946 1876-4479 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2190109593 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Adult Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - adverse effects Anti-Inflammatory Agents - therapeutic use Crohn Disease - complications Crohn Disease - drug therapy Female Follow-Up Studies Humans Intestinal Obstruction - epidemiology Intestinal Obstruction - etiology Intestinal Obstruction - prevention & control Male Middle Aged Prospective Studies Switzerland Time Factors Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A35%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20Initiation%20of%20Anti-TNF%20is%20Associated%20with%20Favourable%20Long-term%20Outcome%20in%20Crohn's%20Disease:%2010-Year-Follow-up%20Data%20from%20the%20Swiss%20IBD%20Cohort%20Study&rft.jtitle=Journal%20of%20Crohn's%20and%20colitis&rft.au=Frei,%20Roy&rft.date=2019-09-27&rft.volume=13&rft.issue=10&rft.spage=1292&rft.epage=1301&rft.pages=1292-1301&rft.issn=1873-9946&rft.eissn=1876-4479&rft_id=info:doi/10.1093/ecco-jcc/jjz057&rft_dat=%3Cproquest_cross%3E2190109593%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2190109593&rft_id=info:pmid/30854548&rfr_iscdi=true |